Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Start-Up Quarterly Statistics, Q1 2012

This article was originally published in Start Up

Executive Summary

Biopharma start-ups raised $338.1 million – 51% less than in Q4 2011. Device companies brought in $123.7 million and diagnostics firms raised $99.3 million; Series C rounds generated more money in both the device and diagnostic sectors than any other financing type. Cancer was the most prevalent therapeutic area for biopharma alliances. During Q1, M&As across biopharma and diagnostic industries were valued at a total of $471 million.

You may also be interested in...



Shire Buys FerroKin BioSciences To Further Hematology Strategy

Shire gains an iron chelator in Phase II development in exchange for $100 million upfront and post-closing milestones of $225 million.

Acorda Expands Pipeline With Neuronex And New Ampyra Indications

Acorda Therapeutics reports strong Ampyra results in the fourth quarter and highlights the other indications it’s pursuing for the drug, as well as the consumer marketing campaign the company is about to undertake. Acorda also announced its intention to acquire privately-held Neuronex Inc. for $2 million upfront plus $500,000 in R&D funding.

Verastem Joins The Public Markets With A Strong IPO

Verastem IPO’d at $10 per share on Jan. 26, despite having only preclinical assets in its pipeline. Strong interest from large companies for cancer stem cell therapies helped contribute to the price.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID1132281

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel